Enzymatica (ENZY) Study Result summary

Study design and methodology

• Combined in vivo (randomized, double-blind, placebo-controlled trial in 160+ endurance athletes) and in vitro (human airway epithelial cell models) approaches to assess ColdZyme's effects on upper respiratory tract infections.

• Participants used ColdZyme or placebo at the onset of symptoms or optionally as prevention when at increased risk, with symptoms, training, and product use monitored for up to three months.

• Swabs were collected for pathogen screening and viral load measurement, with comprehensive analysis of 41 pathogens.

• In vitro studies used air-liquid interface and organoid models to assess ColdZyme's impact on viral infectivity, adhesion, replication, and tissue integrity.

• The studies were independently designed, double-blind, pre-registered, and peer-reviewed, ensuring scientific rigor.

Key findings and results

• ColdZyme significantly reduced the duration of upper respiratory infection episodes and rhinovirus viral load by 94% compared to placebo (P = 0.029).

• Symptom severity scores (Jackson score) and number of sick days were significantly lower in the ColdZyme group, with statistical significance across multiple symptoms (P values 0.004–0.016).

• Viral load, especially for rhinovirus, was significantly lower in the ColdZyme group, explaining reduced symptoms and duration.

• In vitro, ColdZyme pre-treatment reduced viral infectivity, viral load, and tissue damage in airway epithelial models.

• ColdZyme's effect extended to reducing viral loads for SARS-CoV-2 variants and Influenza A/B in previous studies.

Mechanistic insights and broader implications

• ColdZyme acts by reducing viral propagation, limiting spread from cell to cell, and thus breaking the virus cycle.

• Lower viral load leads to less tissue damage and reduced symptom severity, supported by both in vivo and in vitro data.

• The epithelial barrier and mucociliary clearance are crucial in preventing infection; ColdZyme helps maintain this barrier.

• Results in athletes are expected to translate to the general population due to similar infection mechanisms.

• ColdZyme addresses the root cause of colds by inhibiting viral infection and spread, not just alleviating symptoms.